Point72 Asset Management L.P. bought a new stake in Allergan PLC. (NYSE:AGN) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 449,776 shares of the company’s stock, valued at approximately $92,182,000. Point72 Asset Management L.P. owned about 0.14% of Allergan as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in AGN. Vanguard Group Inc. grew its stake in shares of Allergan by 2.2% during the second quarter. Vanguard Group Inc. now owns 22,835,689 shares of the company’s stock valued at $5,551,128,000 after buying an additional 482,220 shares during the last quarter. Northern Trust Corp boosted its holdings in shares of Allergan by 8.8% during the second quarter. Northern Trust Corp now owns 4,492,944 shares of the company’s stock worth $1,092,189,000 after purchasing an additional 364,722 shares during the period. Edgewood Management LLC boosted its holdings in shares of Allergan by 24.3% during the third quarter. Edgewood Management LLC now owns 4,445,924 shares of the company’s stock worth $911,192,000 after purchasing an additional 869,248 shares during the period. Baupost Group LLC MA boosted its holdings in shares of Allergan by 21.9% during the third quarter. Baupost Group LLC MA now owns 2,964,203 shares of the company’s stock worth $607,513,000 after purchasing an additional 531,600 shares during the period. Finally, Epoch Investment Partners Inc. boosted its holdings in shares of Allergan by 1.0% during the third quarter. Epoch Investment Partners Inc. now owns 1,805,608 shares of the company’s stock worth $370,060,000 after purchasing an additional 17,068 shares during the period. 81.34% of the stock is currently owned by institutional investors and hedge funds.

In other Allergan news, Director Chris W. Bodine bought 3,030 shares of the stock in a transaction dated Thursday, December 7th. The stock was purchased at an average cost of $164.77 per share, for a total transaction of $499,253.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Christopher J. Coughlin bought 10,000 shares of the stock in a transaction dated Tuesday, December 5th. The shares were acquired at an average price of $163.30 per share, with a total value of $1,633,000.00. The disclosure for this purchase can be found here. Insiders acquired 17,630 shares of company stock valued at $2,890,057 over the last 90 days. 0.36% of the stock is currently owned by company insiders.

A number of analysts have recently weighed in on the stock. Wells Fargo & Company reiterated an “outperform” rating on shares of Allergan in a report on Monday, September 11th. Argus reiterated a “buy” rating and set a $280.00 target price on shares of Allergan in a report on Monday, August 14th. Deutsche Bank reiterated a “buy” rating and set a $262.00 target price on shares of Allergan in a report on Tuesday, September 12th. BidaskClub lowered shares of Allergan from a “hold” rating to a “sell” rating in a report on Thursday, August 17th. Finally, Cantor Fitzgerald reiterated a “hold” rating on shares of Allergan in a report on Tuesday, August 29th. One analyst has rated the stock with a sell rating, nine have issued a hold rating and thirteen have assigned a buy rating to the company. Allergan has an average rating of “Buy” and an average price target of $235.25.

Shares of Allergan PLC. (AGN) opened at $167.80 on Monday. The company has a quick ratio of 1.08, a current ratio of 1.18 and a debt-to-equity ratio of 0.40. Allergan PLC. has a 1-year low of $160.07 and a 1-year high of $256.80. The company has a market cap of $55,807.45, a PE ratio of 10.88, a price-to-earnings-growth ratio of 1.12 and a beta of 1.11.

Allergan (NYSE:AGN) last issued its quarterly earnings data on Wednesday, November 1st. The company reported $4.15 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $4.06 by $0.09. Allergan had a negative net margin of 47.27% and a positive return on equity of 8.00%. The business had revenue of $4.03 billion during the quarter, compared to analyst estimates of $4.04 billion. During the same period last year, the business posted $3.32 earnings per share. Allergan’s quarterly revenue was up 11.4% compared to the same quarter last year. equities analysts anticipate that Allergan PLC. will post 16.27 EPS for the current fiscal year.

Allergan declared that its board has initiated a stock buyback plan on Monday, September 25th that allows the company to buyback $2.00 billion in shares. This buyback authorization allows the company to purchase up to 2.8% of its stock through open market purchases. Stock buyback plans are typically a sign that the company’s board believes its shares are undervalued.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 15th. Shareholders of record on Friday, November 17th will be issued a $0.70 dividend. The ex-dividend date of this dividend is Thursday, November 16th. This represents a $2.80 annualized dividend and a yield of 1.67%. Allergan’s dividend payout ratio (DPR) is presently -12.44%.

ILLEGAL ACTIVITY NOTICE: “449,776 Shares in Allergan PLC. (AGN) Purchased by Point72 Asset Management L.P.” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://www.thecerbatgem.com/2017/12/11/449776-shares-in-allergan-plc-agn-purchased-by-point72-asset-management-l-p.html.

Allergan Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Institutional Ownership by Quarter for Allergan (NYSE:AGN)

Receive News & Stock Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related stocks with our FREE daily email newsletter.